All Stories

  1. Telehealth at scale can improve chronic disease management in the community during a pandemic: An experience at the time of COVID-19
  2. Does Dietary Salt Loading Impair Ambulatory Blood Pressure Variability? As Yet an Unresolved Issue
  3. Ethnic disparities in the morning surge: Which utility for typifying the hypertensive patient?
  4. Blood pressure related to age: The India ABPM study
  5. Ambulatory blood pressure and arterial stiffness web‐based telemonitoring in patients at cardiovascular risk. First results of the VASOTENS (Vascular health ASsessment Of The hypertENSive patients) Registry
  6. Connected Health in Hypertension Management
  7. Telemonitoring of 24-Hour Blood Pressure in Local Pharmacies and Blood Pressure Control in the Community: The Templar Project
  8. Efficacy of Zofenopril Alone or in Combination with Hydrochlorothiazide in Patients with Kidney Dysfunction
  9. Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan
  10. Pharmacist-led hypertension management combined with blood pressure telemonitoring in a primary care setting may be cost-effective in high-risk patients
  11. Physician–pharmacist collaborative practice and telehealth may transform hypertension management
  12. MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol
  13. Simultaneous double arm automated blood pressure measurement for the screening of subjects with potential vascular disease: a community study
  14. Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan
  15. A17826 Cuff blood pressure is progressively more biased with increasing age
  16. Effects on 24-hour blood pressure variability of ace-inhibition and calcium channel blockade as monotherapy or in combination
  17. Has the time come for self-management of blood pressure and antihypertensive medications by patients?
  18. Efficacy of zofenopril in combination with amlodipine in patients with acute myocardial infarction: a pooled individual patient data analysis of four randomized, double-blind, controlled, prospective studies
  19. A working definition of white-coat hypertension must include nocturnal blood pressure
  20. Efficacy of zofenopril in combination with thiazide diuretics in patients with acute myocardial infarction: a pooled individual data analysis of four randomized, double-blind, controlled, prospective studies
  21. Home blood pressure telemonitoring in the 21st century
  22. Telepharmacy for the management of cardiovascular patients in the community
  23. Effects of the concomitant administration of xanthine oxidase inhibitors with zofenopril or other ACE-inhibitors in post-myocardial infarction patients: a meta-analysis of individual data of four randomized, double-blind, prospective studies
  24. AN ABNORMAL BETWEEN-ARM BLOOD PRESSURE DIFFERENCE IS ASSOCIATED WITH CARDIOVASCULAR RISK FACTORS AND DISEASE
  25. Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublished Data of the Randomized Double-Blind SMILE-4 Study
  26. Effect of antihypertensive treatment on 24-h blood pressure variability
  27. Effectiveness of pharmacist’s intervention in the management of cardiovascular diseases
  28. Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis
  29. [OP.7D.07] 24-HOUR CENTRAL BLOOD PRESSURE IS BETTER ASSOCIATED WITH TARGET ORGAN DAMAGE OF HYPERTENSION THAN BRACHIAL BLOOD PRESSURE
  30. [PP.09.20] AMBULATORY VASCULAR INDEX
  31. [PP.12.09] MASKED-UNCONTROLLED HYPERTENSION MANAGEMENT BASED ON OFFICE BP OR ON OUT-OF-OFFICE (AMBULATORY) BP MEASUREMENT (MASTER)
  32. Masked Uncontrolled Hypertension in the Elderly: A Dangerous Affair
  33. Olmesartan vs ramipril in the treatment of hypertension and associated clinical conditions in the elderly: a reanalysis of two large double-blind, randomized studies at the light of the most recent blood pressure targets recommended by guidelines [Corr...
  34. Accuracy of Cuff-Measured Blood Pressure
  35. Efficacy of Ace Inhibition with Zofenopril, Lisinopril, or Ramipril in Postacute Myocardial Infarction Patients With or Without Metabolic Syndrome: A Pooled Individual Data Analysis of Four Randomized, Double-Blind, Controlled, Prospective Studies
  36. Smartphone Applications for Hypertension Management: a Potential Game-Changer That Needs More Control
  37. Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction
  38. Erratum to: Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized “Z” Studies
  39. Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized “Z” Studies
  40. Cardioprotective role of zofenopril in hypertensive patients with acute myocardial infarction: a pooled individual data analysis of the SMILE studies
  41. Efficacy of Zofenopril Compared With Placebo and Other Angiotensin-converting Enzyme Inhibitors in Patients With Acute Myocardial Infarction and Previous Cardiovascular Risk Factors
  42. Relationships between 24-h blood pressure variability and 24-h central arterial pressure, pulse wave velocity and augmentation index in hypertensive patients
  43. Hypertension types defined by clinic and ambulatory blood pressure in 14 143 patients referred to hypertension clinics worldwide. Data from the ARTEMIS study
  44. Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic S...
  45. Zofenopril and ramipril in patients with left ventricular systolic dysfunction after acute myocardial infarction: A propensity analysis of the Survival of Myocardial Infarction Long-term Evaluation (SMILE) 4 study
  46. Twenty-Four-Hour Ambulatory Pulse Wave Analysis in Hypertension Management: Current Evidence and Perspectives
  47. [PP.01.25] INTERNATIONAL REGISTRY FOR AMBULATORY BLOOD PRESSURE AND ARTERIAL STIFFNESS TELEMONITORING (VASOTENS REGISTRY)
  48. [OP.6B.04] INDIVIDUAL PATIENT DATA META-ANALYSIS OF SELF-MONITORING OF BLOOD PRESSURE (BP-SMART)
  49. Methodology and technology for peripheral and central blood pressure and blood pressure variability measurement
  50. Do arterial stiffness and wave reflections improve more with angiotensin receptor blockers than with other antihypertensive drug classes?
  51. Vascular Health Assessment of The Hypertensive Patients (VASOTENS) Registry: Study Protocol of an International, Web-Based Telemonitoring Registry for Ambulatory Blood Pressure and Arterial Stiffness
  52. Telemedicine and M-Health in Hypertension Management: Technologies, Applications and Clinical Evidence
  53. Opportunistic screening of atrial fibrillation by automatic blood pressure measurement in the community: Table 1
  54. Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients
  55. Zofenopril or irbesartan plus hydrochlorothiazide in elderly patients with isolated systolic hypertension untreated or uncontrolled by previous treatment
  56. Screening for atrial fibrillation with automated blood pressure measurement: Research evidence and practice recommendations
  57. Effects of the lercanidipine–enalapril combination vs. the corresponding monotherapies on home blood pressure in hypertension
  58. Erratum to: Early (≤1-h) vs. late (>1-h) administration of frovatriptan plus dexketoprofen combination vs. frovatriptan monotherapy in the acute treatment of migraine attacks with or without aura: a post hoc analysis of a double-blind, randomized, para...
  59. Olmesartan vs ramipril in the treatment of hypertension and associated clinical conditions in the elderly: a reanalysis of two large double blind, randomized studies at the light of the most recent blood pressure targets recommended by guidelines
  60. Ethnic Differences in the Degree of Morning Blood Pressure Surge and in Its Determinants Between Japanese and European Hypertensive Subjects
  61. Standards for ambulatory blood pressure monitoring clinical reporting in daily practice
  62. Cardioprotective role of zofenopril in patients with acute myocardial infarction: a pooled individual data analysis of four randomised, double-blind, controlled, prospective studies
  63. Individual patient data meta-analysis of self-monitoring of blood pressure (BP-SMART): a protocol: Table 1
  64. Randomised comparison of zofenopril and ramipril plus acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a post hoc analysis of the SMILE-4 Study in patients according to levels of left ventricular ej...
  65. Home or ambulatory blood pressure monitoring for the diagnosis of hypertension?
  66. 3D.05
  67. PP.LB02.09
  68. Early (≤1-h) vs. late (>1-h) administration of frovatriptan plus dexketoprofen combination vs. frovatriptan monotherapy in the acute treatment of migraine attacks with or without aura: a post hoc analysis of a double-blind, randomized, parallel group s...
  69. Efficacy of frovatriptan as compared to other triptans in migraine with aura
  70. The Role of Telemedicine in Hypertension Management: Focus on Blood Pressure Telemonitoring
  71. The pharmacist and the management of arterial hypertension: the role of blood pressure monitoring and telemonitoring
  72. Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial
  73. Evaluation of 24-Hour Arterial Stiffness Indices and Central Hemodynamics in Healthy Normotensive Subjects versus Treated or Untreated Hypertensive Patients: A Feasibility Study
  74. Effects of Treatment with Zofenopril in Men and Women with Acute Myocardial Infarction: Gender Analysis of the SMILE Program
  75. EHMTI-0052. Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without aura
  76. Zofenopril plus hydrochlorothiazide combination in the treatment of hypertension: an update
  77. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring
  78. Efficacy of frovatriptan and other triptans in the treatment of acute migraine of normal weight and obese subjects: a review of randomized studies
  79. Gender and triptan efficacy: a pooled analysis of three double-blind, randomized, crossover, multicenter, Italian studies comparing frovatriptan vs. other triptans
  80. Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without aura
  81. CARDIOPROTECTIVE ROLE OF ZOFENOPRIL IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION: THE EXPERIENCE OF THE SMILE PROGRAM
  82. COST EFFECTIVENESS OF ZOFENOPRIL IN THE TREATMENT OF PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION AFTER ACUTE MYOCARDIAL INFARCTION: A POST-HOC ANALYSIS OF THE SMILE-4 STUDY
  83. Olmesartan vs. Ramipril in Elderly Hypertensive Patients: Review of Data from Two Published Randomized, Double-Blind Studies
  84. Zofenopril Plus Hydrochlorothiazide and Irbesartan Plus Hydrochlorothiazide in Previously Treated and Uncontrolled Diabetic and Non-diabetic Essential Hypertensive Patients
  85. Frovatriptan versus other triptans in the acute treatment of migraine with aura attacks: Pooled analysis of double-blind, randomized, cross-over, multicenter, studies
  86. Relapse in acute migraine treatment: Comparison of frovatriptan with other triptans
  87. European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring
  88. Cardiac index assessment: Validation of a new non-invasive very low current thoracic bioimpedance device by thermodilution
  89. Cardioprotective role of zofenopril in patients with acute myocardial infarction: high-risk subgroup analysis of the SMILE OVERALL project
  90. Zofenopril is a cost-effective treatment for patients with left ventricular systolic dysfunction following acute myocardial infarction: a pharmacoeconomic analysis of the SMILE-4 study
  91. Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMILE-4
  92. Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction
  93. Frovatriptan vs. other triptans for the acute treatment of oral contraceptive-induced menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies
  94. Efficacy of frovatriptan and other triptans in the treatment of acute migraine of hypertensive and normotensive subjects: a review of randomized studies
  95. Cost effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post- hoc analysis of the smile-4 study
  96. Long-term blood pressure changes induced by the 2009 L’Aquila earthquake: assessment by 24h ambulatory monitoring
  97. Awareness, treatment, and control of major cardiovascular risk factors in a small-scale Italian community: results of a screening campaign
  98. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring
  99. Frovatriptan vs other triptans in the treatment of menstrual migraine: pooled analysis of three double-blind, randomized, cross-over studies
  100. Frovatriptan vs almotriptan for treatment of menstrual migraine: a double-blind, randomized, cross-over, multicenter Italian study
  101. Symptomatic or prophylactic treatment of weekend migraine: an open-label, nonrandomized, comparison study of frovatriptan versus naproxen sodium versus no therapy
  102. Efficacy and safety of ribosome-component immune modulator for preventing recurring respiratory infections in socialized children
  103. Blood pressure control and treatment adherence in hypertensive patients with metabolic syndrome: protocol of a randomized controlled study based on home blood pressure telemonitoring vs. conventional management and assessment of psychological determina...
  104. Frovatriptan vs other triptans in the treatment of menstrual migraine: pooled analysis of three double-blind, randomized, cross-over studies
  105. Frovatriptan vs almotriptan for treatment of menstrual migraine: a double-blind, randomized, cross-over, multicenter Italian study
  106. Antihypertensive Efficacy of Olmesartan Medoxomil and Ramipril in Elderly Patients with Mild to Moderate Hypertension Grouped According to Renal Function Status
  107. Antihypertensive Efficacy and Safety of Olmesartan Medoxomil and Ramipril in Elderly Mild to Moderate Essential Hypertensive Patients With or Without Metabolic Syndrome
  108. 564 ZOFENOPRIL AND RAMIPRIL PLUS ASA IN POST- MYOCARDIAL INFARCTION PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION
  109. Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients
  110. Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study
  111. Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double-blind, randomized, multicenter, Italian study
  112. Efficacy of frovatriptan versus other triptans in the acute treatment of menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies
  113. Efficacy and safety of ribosome-component immune modulator for preventing recurrent respiratory infections in socialized children
  114. Zofenopril and incidence of cough: a review of published and unpublished data
  115. Suggested randomized, controlled trial for frovatriptan: a reply
  116. Impact of Home Blood Pressure Telemonitoring and Blood Pressure Control: A Meta-Analysis of Randomized Controlled Studies
  117. Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan
  118. DIAGNOSTIC ACCURACY OF HOME BLOOD PRESSURE MONITORING: THE MEDIT-HABP STUDY (MEDITERRANEAN HOME VS. AMBULATORY BP)
  119. PREDICTORS OF ISOLATED CLINIC AND MASKED HYPERTENSION BASED ON HOME OR AMBULATORY BLOOD PRESSURE: THE MEDIT-HABP (MEDITERRANEAN HOME VS. AMBULATORY BP) STUDY
  120. HYPERTENSION PHENOTYPES DEFINED BY OFFICE AND AMBULATORY BLOOD PRESSURE IN 9,153 SUBJECTS REFERRED TO HYPERTENSION CLINICS IN FOUR CONTINENTS: THE ARTEMIS INTERNATIONAL REGISTRY
  121. When to use frovatriptan in migraine? A reply
  122. Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, multicenter, Italian, comparative study versus zolmitriptan
  123. Frovatriptan versus other triptans in the acute treatment of migraine: pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies
  124. Restless legs syndrome is not associated with migraine with aura: a clinical study
  125. A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine
  126. Role of home blood pressure telemonitoring in hypertension management
  127. Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension
  128. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study
  129. A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine
  130. Effectiveness of barnidipine 10 or 20 mg plus losartan 50-mg combination versus losartan 100-mg monotherapy in patients with essential hypertension not controlled by losartan 50-mg monotherapy: A 12-week, multicenter, randomized, open-label, parallel-g...
  131. ANTIHYPERTENSIVE EFFICACY AND SAFETY OF OLMESARTAN AND RAMIPRIL IN ELDERLY PATIENTS WITH MILD TO MODERATE SYSTOLIC AND DIASTOLIC ESSENTIAL HYPERTENSION: HT.1.02
  132. ANTIHYPERTENSIVE EFFICACY AND SAFETY OF OLMESARTAN MEDOXOMIL AND RAMIPRIL IN ELDERLY PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION: THE ESPORT STUDY: HT.1.03
  133. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study
  134. Time-weighted vs. conventional quantification of 24-h average systolic and diastolic ambulatory blood pressures
  135. Zofenopril Plus Hydrochlorothiazide Fixed Combination in the Treatment of Hypertension and Associated Clinical Conditions
  136. Why Is Out-of-Office Blood Pressure Measurement Needed?
  137. Home Blood Pressure Measurements Will Not Replace 24-Hour Ambulatory Blood Pressure Monitoring
  138. Home blood pressure telemonitoring improves hypertension control in general practice. The TeleBPCare study
  139. PA.NET International Quality Certification Protocol for blood pressure monitors
  140. Antihypertensive effect of zofenopril plus hydrochlorothiazide versus zofenopril monotherapy in patients with essential hypertension according to their cardiovascular risk level: A post hoc analysis
  141. Validation of the Artsana CS 410 automated blood pressure monitor in adults according to the International Protocol of the European Society of Hypertension
  142. Antihypertensive effect of barnidipine 10 mg or amlodipine 5 to 10 mg once daily in treatment-naive patients with essential hypertension: A 24-week, randomized, open-label, pilot study
  143. Italian Society of Hypertension Guidelines for Conventional and Automated Blood Pressure Measurement in the Office, at Home and Over 24 Hours
  144. Circadian Blood Pressure Profile in Patients with Active Cushing's Disease and after Long-term Cure
  145. Antihypertensive efficacy of zofenopril plus hydrochlorothiazide fixed combination for treatment in metabolic syndrome
  146. Short Duration of Sleep and Unintentional Injuries among Adolescents in China
  147. Validation of the Omron M5-I, R5-I and HEM-907 automated blood pressure monitors in elderly individuals according to the International Protocol of the European Society of Hypertension
  148. Frovatriptan for The Prevention of Postdural Puncture Headache
  149. Validation of the Artsana CSI 610 automated blood pressure monitor in adults according to the International Protocol of the European Society of Hypertension
  150. Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis
  151. Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutics
  152. Vascular risk factors in glaucoma: the results of a national survey
  153. Antihypertensive efficacy of zofenopril and hydrochlorothiazide combination on ambulatory blood pressure
  154. A similar 24‐h blood pressure control is obtained by zofenopril and candesartan in primary hypertensive patients
  155. Zofenopril versus Lisinopril in the Treatment of Essential Hypertension in Elderly Patients
  156. ArterialPressure.net
  157. Web-Based Telemonitoring of Home Blood Pressure in General Practice
  158. Measurement Home Blood Pressure
  159. EFFICACY AND TOLERABILITY OF CANDESARTAN 16 MG + HYDROCHLOROTHIAZIDE 12.5 MG FIXED COMBINATION VS. PREVIOUS MONOTHERAPY + HYDROCHLOROTHIAZIDE IN ESSENTIAL HYPERTENSION
  160. REFERENCE VALUES FOR CLINICAL USE OF THE SMOOTHNESS INDEX
  161. ARM AND WRIST AUTOMATED OSCILLOMETRIC SPHYGMOMA-NOMETERS
  162. TELEMONITORING OF HOME BLOOD PRESSURE IMPROVES BLOOD PRESSURE CONTROL IN HYPERTENSION
  163. DIFFERENT MEASURES OF 24 H BLOOD PRESSURE VARIABILITY AND ITS NOCTURNAL FALL IN RELATION TO LEFT VENTRICULAR STRUCTURE AND FUNCTION IN HYPERTENSION. EVIDENCE FROM THE SAMPLE STUDY
  164. TIME-WEIGHTED VS CONVENTIONAL QUANTIFICATION OF 24 HOUR AVERAGE AMBULATORY SYSTOLIC BLOOD PRESSURE
  165. Time-weighted vs conventional quantification of 24 H average systolic and diastolic ambulatory blood pressures
  166. Candesartan plus hydrochlorothiazide fixed combination vs previous monotherapy plus diuretic in poorly controlled essential hypertensive patients
  167. Combination of lisinopril and nifedipine GITS Increases Blood Pressure Control Compared with Single Drugs in Essential Hypertensive Patients
  168. Switching from ACE Inhibitors, Beta-blockers, Calcium Antagonists or Diuretics to Candesartan Improves Efficacy and Tolerability
  169. Twenty-four hour ambulatory blood pressure in the International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT)
  170. Smooth Blood Pressure Control Obtained with Extended-Release Felodipine in Elderly Patients with Hypertension
  171. Mechanisms underlying the impairment in orthostatic tolerance after nocturnal recumbency in patients with autonomic failure
  172. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA)
  173. Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study
  174. Efficacy, Tolerability, and Impact on Quality of Life of Long-Term Treatment with Manidipine or Amlodipine in Patients with Essential Hypertension
  175. Reproducibility of beat-by-beat blood pressure and heart rate variability
  176. Comparison of candesartan versus enalapril in essential hypertension
  177. A Smooth Blood Pressure Control is obtained over 24 h by Delapril in Mild to Moderate Essential Hypertensives
  178. Long-term efficacy of sertraline in major depression: A study with plasma levels
  179. Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutics
  180. Antihypertensive Efficacy of Manidipine and Enalapril in Hypertensive Diabetic Patients
  181. TIME COURSE OF DIRECT AND INDIRECT MEASURES OF WHITE COAT EFFECT OVER REPEATED VISITS
  182. ASSESSING WHITE COAT EFFECT
  183. The importance of blood pressure variability in hypertension
  184. Transient photoconductivity, density of tail states and doping effect in amorphous silicon
  185. Broad-band spectral analysis of 24 h continuous finger blood pressure: comparison with intra-arterial recordings
  186. Clinical value of ambulatory blood pressure monitoring
  187. Ambulatory Blood Pressure Monitoring
  188. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements
  189. Clinical Advantages of Lipophilic Dihydropyridines
  190. The smoothness index
  191. Reproducibility and Clinical Value of the Trough-to-Peak Ratio of the Antihypertensive Effect
  192. Estimation of Blood Pressure Variability From 24-Hour Ambulatory Finger Blood Pressure
  193. Risk factors associated with alterations in carotid intima—media thickness in hypertension
  194. Reproducibility and clinical value of nocturnal hypotension
  195. Difference Between Clinic and Daytime Blood Pressure Is Not a Measure of the White Coat Effect
  196. Clinical Advantages of Lipophilic Dihydropyridines
  197. Limitations of the difference between clinic and daytime blood pressure as a surrogate measure of the ‘white-coat’ effect
  198. Hemodynamic Changes in the Lower Limbs During Treadmill Walking in Normal Subjects and in Patients with Arteriosclerosis Obliterans
  199. Combination treatment in hypertension the VeraTran Study
  200. Performance of the AM-5600 blood pressure monitor: comparison with ambulatory intra-arterial pressure
  201. Assessment of antihypertensive treatment by ambulatory blood pressure
  202. Ambulatory blood pressure monitoring
  203. Twenty four hour continuous non-invasive finger blood pressure monitoring: a novel approach to the evaluation of treatment in patients with autonomic failure
  204. Difference between office and ambulatory blood pressure and response to antihypertensive treatment
  205. Blood pressure and heart rate variability in autonomic disorders: a critical review
  206. Lack of effect of percutaneous transluminal renal angioplasty on nocturnal hypotension in renovascular hypertensive patients
  207. Ambulatory Blood Pressure, Blood Pressure Variability and Antihypertensive Treatment
  208. Analysis of Heart Rate and Blood Pressure Variability in the Assessment of Autonomic Regulation in Arterial Hypertension
  209. Blood pressure variability, cardiovascular risk and antihypertensive treatment
  210. Calculation of trough: peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects
  211. Permanent Blood Pressure Control Over the 24 h by Trandolapril
  212. Structural cardiovascular alterations and blood pressure variability in human hypertension
  213. Blood pressure variability over 24 hours: its different components and its relationship to the arterial baroreflex
  214. Twenty four hour continuous non-invasive finger blood pressure monitoring: a novel approach to the evaluation of treatment in patients with autonomic failure.
  215. Lack of placebo effect on ambulatory blood pressure
  216. Prognostic value of ambulatory blood pressure monitoring
  217. The ambulatory blood pressure in normotensive and hypertensive subjects: results from an international database*1
  218. Ambulatory Blood Pressure Monitoring in the Evaluation of Antihypertensive Treatment: Additional Information from a Large Data Base
  219. Blood pressure reduction and end-organ damage in hypertension
  220. Ambulatory blood pressure monitoring in the evaluation of antihypertensive drugs
  221. Twenty-Four-Hour Ambulatory Blood Pressure Monitoring and Antihypertensive Treatment
  222. Ambulatory blood pressure in normotensive and hypertensive subjects
  223. Clinical Value of Ambulatory Blood Pressure Monitoring
  224. Antihypertensive effects of nifedipine gastrointestinal therapeutic system on clinic and ambulatory blood pressure in essential hypertensives
  225. 151 Twenty-four hour non-invasive ambulatory blood pressure monitoring by AM5600 versus simultaneous intra-arterial recording in essential hypertensives
  226. Impairment of the arterial baroreflex during symptomatic and silent myocardial ischemia in humans
  227. Spectral and sequence analysis of finger blood pressure variability. Comparison with analysis of intra-arterial recordings.
  228. Ambulatory Blood Pressure Monitoring in the Design of Studies on Antihypertensive Drug Efficacy
  229. Spectral Analysis of 24 h Blood Pressure Recordings
  230. Isobaric compliance of the radial artery is increased in patients with essential hypertension
  231. Ambulatory blood pressure monitoring and antihypertensive treatment
  232. Limited reproducibility of hourly blood pressure values obtained by ambulatory blood pressure monitoring
  233. Clinical value of blood pressure measurements: Focus on ambulatory blood pressures
  234. Evaluation of the antihypertensive effect of once-a-day trandolapril by 24-hour ambulatory blood pressure monitoring
  235. Noninvasive Automatic Blood Pressure Monitoring Does Not Attenuate Nighttime Hypotension
  236. Variability in arterial diameter and compliance
  237. Evaluation of noninvasive blood pressure monitoring devices Spacelabs 90202 and 90207 versus resting and ambulatory 24-hour intra-arterial blood pressure.
  238. Persistent blood pressure increase induced by heavy smoking
  239. Sympathomoderating influence of benazepril in essential hypertension
  240. Ambulatory Blood Pressure Monitoring
  241. Dynamic Evaluation of Neural Cardiovascular Regulation Through the Analysis of Blood Pressure and Pulse Interval Variability over 24 Hours
  242. Acute modulation of arterial compliance in mild essential hypertension
  243. Effect of ageing on blood pressure variability
  244. Validation of the SpaceLabs 90202 and 90207 devices for ambulatory blood pressure monitoring by comparison with intra-arterial resting and ambulatory measurements
  245. Role of sinoaortic afferents in modulating BP and pulse-interval spectral characteristics in unanesthetized cats
  246. Effect of placebo on 24-h non-invasive ambulatory blood pressure
  247. Methodological problems in evaluation of cardiovascular effects of stress in humans.
  248. Acute modulation of arterial compliance in mild essential hypertension
  249. Effect of ageing on blood pressure variability
  250. Validation of the SpaceLabs 90202 and 90207 devices for ambulatory blood pressure monitoring by comparison with intra-arterial resting and ambulatory measurements
  251. Sequential spectral analysis of 24-hour blood pressure and pulse interval in humans.
  252. Cardiovascular Effects of Smoking
  253. Clinical and Hemodynamic Effects of Celiprolol in Essential Hypertension
  254. Clinical and Hemodynamic Effects of Celiprolol in Essential Hypertension
  255. Commemorazione del Barone Achille de Zigno.
  256. Influencers of the selection between heart-period and heart-rate on the spectral evaluation of heart rhythm variability during exercise
  257. Evaluation Of Neural Cardiovascular Control Through Dynamic Analysis Of 24 Hour Blood Pressure And Heart Rate
  258. Prognostic Value of Ambulatory Blood Pressure Monitoring